|
|
Implant Biofilm Mediated Immune Response |
| 1R01AI165958-01A1 |
|
NIAID |
2022 |
|
|
Monitoring Treatment Efficacy in Leprosy |
| 1R21AI171254-01 |
|
NIAID |
2022 |
|
|
Novel Biofilm Paradigm Explaining Clinical Implant-Associated Illness. |
| 1R21AI171932-01 |
|
NIAID |
2022 |
|
|
Nanoimmunotherapy for chronic immune-mediated diseases |
| 1R41AI170413-01 |
|
NIAID |
2022 |
|
|
Human antibody modification of enterovirus D68 infection |
| 5K08AI156125-02 |
|
NIAID |
2022 |
|
|
COMPUTATIONAL TOOLS FOR THE ANALYSIS OF HIGH-THROUGHPUT IMMUNOGLOBULIN SEQUENCING EXPERIMENTS |
| 5R01AI104739-08 |
|
NIAID |
2022 |
|
|
The Role of IL-II in the development of autoimmune response in multiple sclerosis |
| 5R01AI131238-05 |
|
NIAID |
2022 |
|
|
Biomaterials to study tolerance immune induction kinetics |
| 5R01AI137525-05 |
|
NIAID |
2022 |
|
|
Defining the Role of Molecules Unique to Encephalitogenic T Cells in MS |
| 5R01AI140741-04 |
|
NIAID |
2022 |
|
|
Persistent Post-Viral State of Bacterial Pneumonia Susceptibility and Severity in Down Syndrome |
| 5R01AI141662-04 |
|
NIAID |
2022 |
